Real-time Estimate
Cboe BZX
01:38:06 2024-05-16 pm EDT
|
5-day change
|
1st Jan Change
|
64.96
USD
|
-0.01%
|
|
+0.22%
|
+240.84%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
71.38
|
299.9
|
404.7
|
337.5
|
1,106
|
4,457
|
-
|
-
|
Enterprise Value (EV)
1 |
71.38
|
299.9
|
404.7
|
114.1
|
778.1
|
4,224
|
4,249
|
4,182
|
P/E ratio
|
-1.68
x
|
-9.4
x
|
-6.99
x
|
-4.25
x
|
-29.8
x
|
-49.2
x
|
-37
x
|
-28.2
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
41
x
|
32.1
x
|
17.3
x
|
11.2
x
|
18.8
x
|
253
x
|
221
x
|
612
x
|
EV / Revenue
|
41
x
|
32.1
x
|
17.3
x
|
3.79
x
|
13.2
x
|
239
x
|
210
x
|
574
x
|
EV / EBITDA
|
-
|
-
|
-8.22
x
|
-1.96
x
|
-17.8
x
|
-39.5
x
|
-29.1
x
|
-25.6
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-43.8
x
|
-30.3
x
|
-24.2
x
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-2.28%
|
-3.3%
|
-4.13%
|
Price to Book
|
-
|
-
|
-
|
1.88
x
|
-
|
14.7
x
|
27.5
x
|
25.4
x
|
Nbr of stocks (in thousands)
|
18,588
|
23,803
|
29,220
|
45,914
|
58,002
|
68,598
|
-
|
-
|
Reference price
2 |
3.840
|
12.60
|
13.85
|
7.350
|
19.06
|
64.97
|
64.97
|
64.97
|
Announcement Date
|
3/30/20
|
3/18/21
|
3/17/22
|
3/23/23
|
3/18/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
1.74
|
9.335
|
23.44
|
30.06
|
58.88
|
17.64
|
20.2
|
7.288
|
EBITDA
1 |
-
|
-
|
-49.24
|
-58.25
|
-43.67
|
-106.8
|
-145.8
|
-163.2
|
EBIT
1 |
-43.57
|
-28.75
|
-49.86
|
-58.15
|
-44.25
|
-105.7
|
-125.8
|
-155.3
|
Operating Margin
|
-2,504.25%
|
-307.97%
|
-212.68%
|
-193.41%
|
-75.16%
|
-599.44%
|
-623.03%
|
-2,130.53%
|
Earnings before Tax (EBT)
1 |
-41.85
|
-27.95
|
-50.42
|
-55.43
|
-32.08
|
-91.5
|
-116.4
|
-148.7
|
Net income
1 |
-41.85
|
-27.94
|
-50.33
|
-57.76
|
-32.18
|
-97.06
|
-110.2
|
-148.8
|
Net margin
|
-2,405.29%
|
-299.3%
|
-214.7%
|
-192.13%
|
-54.66%
|
-550.34%
|
-545.57%
|
-2,041.58%
|
EPS
2 |
-2.280
|
-1.340
|
-1.980
|
-1.730
|
-0.6400
|
-1.320
|
-1.756
|
-2.303
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
-
|
-96.45
|
-140.3
|
-172.9
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-546.89%
|
-694.6%
|
-2,372.1%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/30/20
|
3/18/21
|
3/17/22
|
3/23/23
|
3/18/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 S1
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
4.53
|
13.63
|
5.292
|
8.367
|
2.776
|
9.387
|
8.593
|
10.04
|
30.85
|
7.032
|
2.989
|
-
|
3.002
|
4.723
|
-
|
-
|
EBITDA
1 |
-15.24
|
-7.309
|
-16.33
|
-13.68
|
-
|
-15.45
|
-15.51
|
-14.4
|
1.695
|
-22.55
|
-31.6
|
-
|
-34
|
-36.6
|
-
|
-
|
EBIT
1 |
-15.38
|
-7.457
|
-16.49
|
-13.83
|
-20.37
|
-15.59
|
-15.66
|
-14.55
|
1.547
|
-22.7
|
-26.94
|
-
|
-29.18
|
-28.22
|
-
|
-
|
Operating Margin
|
-339.43%
|
-54.71%
|
-311.58%
|
-165.32%
|
-733.75%
|
-166.1%
|
-182.18%
|
-144.88%
|
5.01%
|
-322.75%
|
-901.24%
|
-
|
-972.06%
|
-597.41%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-15.46
|
-7.523
|
-16.32
|
-13.27
|
-18.32
|
-13.27
|
-13.16
|
-11.72
|
6.063
|
-17.92
|
-23.38
|
-
|
-25.18
|
-21.53
|
-
|
-
|
Net income
1 |
-15.17
|
-7.527
|
-18.1
|
-13.27
|
-18.86
|
-13.27
|
-13.16
|
-11.72
|
5.96
|
-17.92
|
-23.5
|
-
|
-25.28
|
-22.96
|
-
|
-
|
Net margin
|
-334.81%
|
-55.23%
|
-341.99%
|
-158.64%
|
-679.54%
|
-141.32%
|
-153.1%
|
-116.72%
|
19.32%
|
-254.81%
|
-786.27%
|
-
|
-842.14%
|
-486.13%
|
-
|
-
|
EPS
2 |
-0.5200
|
-0.2500
|
-0.6000
|
-0.4200
|
-0.4100
|
-0.2800
|
-0.2700
|
-0.2400
|
0.1500
|
-0.2800
|
-0.3520
|
-
|
-0.3680
|
-0.3700
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/17/22
|
5/12/22
|
8/11/22
|
11/14/22
|
3/23/23
|
5/11/23
|
8/14/23
|
11/14/23
|
3/18/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
223
|
327
|
233
|
208
|
275
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
-
|
-96.5
|
-140
|
-173
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-38.5%
|
-12.7%
|
-34%
|
-69.3%
|
-106%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
-
|
-
|
3.900
|
-
|
4.430
|
2.360
|
2.560
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
-
|
-
|
-
|
2.25
|
2
|
2.42
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
12.76%
|
9.9%
|
33.16%
|
Announcement Date
|
3/30/20
|
3/18/21
|
3/17/22
|
3/23/23
|
3/18/24
|
-
|
-
|
-
|
Last Close Price
64.97
USD Average target price
62
USD Spread / Average Target -4.57% Consensus |
1st Jan change
|
Capi.
|
---|
| +240.84% | 4.46B | | +7.75% | 113B | | +10.62% | 106B | | +0.41% | 22.27B | | -12.08% | 22.22B | | -5.99% | 19.43B | | -37.36% | 17.87B | | -4.86% | 17.24B | | +6.60% | 14.29B | | +35.41% | 12.52B |
Bio Therapeutic Drugs
|